Search

Your search keyword '"Flavia Chiuppesi"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Flavia Chiuppesi" Remove constraint Author: "Flavia Chiuppesi"
44 results on '"Flavia Chiuppesi"'

Search Results

1. Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform

2. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus

3. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants

4. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study

5. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy

6. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

7. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

8. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants

9. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

10. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

11. Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids

12. A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

13. Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice.

14. Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells

15. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.

16. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

17. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

18. Adoptive transfer of functional <scp>SARS‐COV</scp> ‐2‐specific immunity from donor graft to hematopoietic stem cell transplant recipients

19. Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults

20. Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection

21. Chimeric Antigen Receptors Targeting Human Cytomegalovirus

22. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

23. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

24. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

25. A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

26. Correction for Chiuppesi et al., 'Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus in Mice'

27. Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex

28. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults

29. Cytomegalovirus-vectored vaccines for HIV and other pathogens

30. Adaptive NK cell reconstitution is associated with better clinical outcomes

31. Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids

32. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

33. Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells

34. Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission

35. Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys

36. Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus

37. Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer

38. Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission

39. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection

40. A new dual-promoter system for cardiomyocyte-specific conditional induction of apoptosis

41. A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection against HSV-1 and HSV-2 Genital Infections

42. Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein

44. Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes

Catalog

Books, media, physical & digital resources